Search results for "model."

showing 10 items of 23664 documents

JNK pathway and heat shock response mediate the survival of C26 colon carcinoma bearing mice fed with the mushroom Pleurotus eryngii var. eryngii wit…

2021

In the last few years, there has been emerging interest in developing treatments against human diseases using natural bioactive content. Here, the powder of the edible mushroom Pleurotus eryngii var. eryngii was mixed with the normal diet of mice bearing C26 colon carcinoma. Interestingly, it was evidenced by a significant increase in the survival rate of C26 tumor-bearing mice accompanied by a significant increase in Hsp90 and Hsp27 protein levels in the tumors. These data were paralleled by a decrease in Hsp60 levels. The mushroom introduced in the diet induced the inhibition of the transcription of the pro-inflammatory cytokines IL-6 and IL-1 exerting an anti-inflammatory action. The eff…

0301 basic medicineNormal dietMAP Kinase Signaling SystemPharmacologyPleurotus03 medical and health sciencesMice0302 clinical medicineHsp27SurvivinAnimalsPleurotus eryngiiHeat shockMushroomMice Inbred BALB CbiologyKinaseGeneral MedicineJNK Pleurotus eryngii cachexia C26 colon carcinomabiology.organism_classificationEdible mushroomDisease Models Animal030104 developmental biology030220 oncology & carcinogenesisColonic NeoplasmsDietary Supplementsbiology.proteinFemaleHeat-Shock ResponseFood SciencePhytotherapyFoodfunction
researchProduct

Weakly coupled map lattice models for multicellular patterning and collective normalization of abnormal single-cell states

2017

We present a weakly coupled map lattice model for patterning that explores the effects exerted by weakening the local dynamic rules on model biological and artificial networks composed of two-state building blocks (cells). To this end, we use two cellular automata models based on: (i) a smooth majority rule (model I) and (ii) a set of rules similar to those of Conway's Game of Life (model II). The normal and abnormal cell states evolve according with local rules that are modulated by a parameter $\kappa$. This parameter quantifies the effective weakening of the prescribed rules due to the limited coupling of each cell to its neighborhood and can be experimentally controlled by appropriate e…

0301 basic medicineNormalization (statistics)Majority ruleTime FactorsFOS: Physical sciencesAbnormal cellPattern Formation and Solitons (nlin.PS)Models BiologicalCell Physiological PhenomenaCombinatorics03 medical and health sciences0302 clinical medicineCell Behavior (q-bio.CB)Physics - Biological PhysicsGame of lifeMathematicsCellular Automata and Lattice Gases (nlin.CG)Artificial networksNonlinear Sciences - Pattern Formation and SolitonsCellular automatonMulticellular organism030104 developmental biologyBiological Physics (physics.bio-ph)030220 oncology & carcinogenesisFOS: Biological sciencesQuantitative Biology - Cell BehaviorBiological systemNonlinear Sciences - Cellular Automata and Lattice GasesCoupled map lattice
researchProduct

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

2021

The neutrophil to lymphocyte ratio (NLR) is a promising predictive and prognostic factor in breast cancer. We investigated its ability to predict disease-free survival (DFS) and overall survival (OS) in patients with luminal A- or luminal B-HER2-negative breast cancer who received neoadjuvant chemotherapy (NACT). Pre-treatment complete blood cell counts from 168 consecutive patients with luminal breast cancer were evaluated to assess NLR. The study population was stratified into NLRlow or NLRhigh according to a cut-off value established by receiving operator curve (ROC) analysis. Data on additional pre- and post-treatment clinical-pathological characteristics were also collected. Kaplan–Mei…

0301 basic medicineOncologyAdultmedicine.medical_specialtyMultivariate analysisNeutrophilsQH301-705.5medicine.medical_treatmentBreast NeoplasmsArticleDisease-Free Survivalpredictive/prognostic biomarkers03 medical and health sciences0302 clinical medicineText miningBreast cancerluminal breast cancerInternal medicineMedicineHumansLymphocytesNeutrophil to lymphocyte ratioBiology (General)Neoadjuvant therapyAgedRetrospective StudiesChemotherapybusiness.industryProportional hazards modelallergologyfungiLuminal breast cancer; Neoadjuvant chemotherapy; Neutrophil to lymphocyte ratio (NLR); Predictive/prognostic biomarkers; Adult; Aged; Breast Neoplasms; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Lymphocytes; Middle Aged; Multivariate Analysis; Neutrophils; Prognosis; Retrospective Studies; Treatment Outcome; Neoadjuvant TherapyHistologyGeneral MedicineMiddle Agedmedicine.diseasePrognosisneutrophil to lymphocyte ratio (NLR)Neoadjuvant Therapy030104 developmental biologyKi-67 AntigenTreatment Outcome030220 oncology & carcinogenesisMultivariate AnalysisPopulation studyFemalebusinessneoadjuvant chemotherapy
researchProduct

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study.

2017

Abstract Purpose Visceral metastasis of breast cancer (BC) is an alarming development and correlates with poor median overall survival. The purpose of this retrospective study is to examine the risk factors for developing visceral metastasis by considering tumor biology and patient characteristics. Methods Using the BRENDA database, the risk factors such as histological and intrinsic subtypes of BC, age at primary diagnosis, grading, nodal status, tumor size and year of primary diagnosis were examined in univariate and multivariate analysis. Categorical variables were compared by using χ2 tests. Furthermore, multivariate Cox proportional hazards regression models, Kaplan–Meier product-limit…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyMultivariate statisticsMultivariate analysisLung NeoplasmsBreast NeoplasmsKaplan-Meier EstimateLogistic regressionMetastasis03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerRisk FactorsInternal medicineMedicineHumansGrading (tumors)AgedProportional Hazards ModelsRetrospective StudiesAged 80 and overChi-Square Distributionbusiness.industryCarcinoma Ductal BreastLiver NeoplasmsUnivariateAge FactorsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.disease030104 developmental biologyLogistic Models030220 oncology & carcinogenesisMultivariate AnalysisSurgeryFemalebusinessBreast (Edinburgh, Scotland)
researchProduct

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French P…

2016

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Cote d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan–Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8–53.8%] versus 44.5…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsDiseaseKaplan-Meier EstimateMetastasis03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineEpidemiologyInternal MedicinemedicineHumansRegistriesskin and connective tissue diseaseseducationSurvival rateAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisSurgeryFemaleFrancebusinessThe breast journal
researchProduct

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

2018

Abstract Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was discovered recently to be upregulated in TNBC. CAR T cells were developed that upon specific recognition of TEM8 secreted immunostimulatory cytokines and killed tumor endothelial cells as well as TEM8-positive TNBC cells. Notably, the TEM8 CAR T cells targeted breast cancer stem–like cells, offsetting the formation of mammospheres relative to nontransduced T cells. Adoptive transfer of TEM8 CAR T cells induced regression of established…

0301 basic medicineOncologyCancer ResearchAdoptive cell transfermedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesCell- and Tissue-Based TherapyReceptors Antigen T-CellApoptosisReceptors Cell SurfaceTriple Negative Breast NeoplasmsTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerAntigenInternal medicineBiomarkers TumorTumor Cells CulturedMedicineAnimalsHumansTriple-negative breast cancerCell Proliferationbusiness.industryMicrofilament ProteinsCancerImmunotherapyTriple Negative Breast Neoplasmsmedicine.diseasePrognosisXenograft Model Antitumor AssaysNeoplasm ProteinsSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisCase-Control StudiesFemaleImmunotherapybusinessFollow-Up StudiesCancer research
researchProduct

c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients

2016

The tyrosine kinase c-met alters signaling cascades such as the BRAF-MAPK and PI3K-PKB pathways. These alterations are involved in the carcinogenesis of type I but not type II ovarian cancer (OC). Therefore, the present study investigated the patterns of c-met expression in a cohort of consecutive patients with OC. c-met expression was determined by immunohistochemical analysis. Differences in c-met overexpression among subgroups of established clinicopathological features, including age, histological subtype, tumor stage, histological grading, post-operative tumor burden and completeness of chemotherapy, were determined by χ2 test. Cox regression analyses were performed to determine the pr…

0301 basic medicineOncologyCancer ResearchPathologymedicine.medical_specialtyC-Metmedicine.medical_treatmentBiologymedicine.disease_cause03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineChemotherapyOncogeneProportional hazards modelArticlesmedicine.diseaseMolecular medicine030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCohortCarcinogenesisOvarian cancerOncology Letters
researchProduct

Increased efficacy of stereotactic ablative radiation therapy after bevacizumab in lung oligometastases from colon cancer.

2018

Aim: Metastases from colorectal cancer are poorly responsive to stereotactic ablative radiation therapy (SABR) due to intratumoral hypoxia. Intratumoral oxygenation is improved by administration of angiogenesis inhibitors. Thus, there could be a clinical synergistic effect of SABR with bevacizumab on metastases from colorectal cancer. The aim of this study was to evaluate the feasibility and efficacy of SABR after bevacizumab in lung oligometastases from colon cancer. Methods: The data of patients with lung metastases from colon cancer who underwent SABR were retrospectively evaluated according to the following inclusion criteria: number of metastases ≤3; lung oligometastases from colon can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabColorectal cancermedicine.medical_treatmentSABR volatility modelRadiosurgery03 medical and health sciences0302 clinical medicineInternal medicineAblative casemedicineHumansAgedRetrospective StudiesLungbusiness.industryGeneral MedicineOxygenationMiddle Agedmedicine.diseaseCombined Modality TherapyRadiation therapyBevacizumab030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisColonic Neoplasmsbusinessmedicine.drugTumori
researchProduct

Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd in…

2017

1061 Background: BRAWO is a German non-interventional study, which enrolled more than 2400 patients (pts) with advanced/metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with EVE and EXE. Main objectives are a) the impact of physical activity on efficacy and quality of life, b) prophylaxis and management of stomatitis in clinical routine, and c) the sequence of therapy when EVE is used in daily clinical practice. Methods: In this update on the results of the 3rd interim analysis (data cut-off 18-Oct-2016) we analyzed under real world conditions the first 1.078 patients followed up until disease progression for their progression-free survival (PFS) events. A two-…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMedizin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerQuality of lifeExemestaneInternal medicineMedicineUntil Disease ProgressionEverolimusbusiness.industryProportional hazards modelInterim analysismedicine.diseaseSurgery030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisNon interventionalbusinessmedicine.drugJournal of Clinical Oncology
researchProduct